Core Insights - Insmed Incorporated reported unaudited total revenues of approximately $144.6 million for the first full quarter of the launch of BRINSUPRI and approximately $172.7 million for full-year 2025 [1] - ARIKAYCE exceeded the upper end of guidance for full-year 2025 with unaudited global revenues of approximately $433.8 million, with expectations for 2026 revenues between $450 million and $470 million [1][3] - The company anticipates topline data from the Phase 3 ENCORE study of ARIKAYCE in patients with MAC lung disease in March or April of 2026, and topline data from the Phase 2b CEDAR study of Brensocatib in the second quarter of 2026 [1][10] Financial Performance - Preliminary unaudited financial results for full-year 2025 show ARIKAYCE revenues of $433.8 million, a 19% increase from $363.7 million in 2024, with U.S. revenues growing by 10% and international revenues by 41% [3][4] - BRINSUPRI generated total revenues of $172.7 million in the U.S. for 2025, marking its first full year of launch [3][4] - Total revenues for Insmed in 2025 are expected to reach approximately $606.4 million, a 67% increase from $363.7 million in 2024 [4] Clinical Developments - Insmed plans to launch BRINSUPRI in the European Union in the first half of 2026, following its approval for treating non-cystic fibrosis bronchiectasis [10] - The company initiated the Phase 3 PALM-ILD study of TPIP in patients with pulmonary hypertension associated with interstitial lung disease in Q4 2025, with additional Phase 3 studies planned for PAH, PPF, and IPF in 2026 [10] - Insmed acquired INS1148, a Phase 2-ready monoclonal antibody, and plans to advance its development in interstitial lung disease and asthma [9][10] Market Position and Strategy - Insmed emphasizes its commitment to delivering first- and best-in-class therapies, with a focus on serious diseases across therapeutic areas including Respiratory, Immunology & Inflammation, and Neuro & Other Rare [2] - The company has a diverse portfolio of approved and investigational medicines, with ongoing research in gene therapy and other innovative technologies [56][57] - Insmed's CEO highlighted the potential for significant growth in the next 18 months due to upcoming clinical and commercial catalysts [2]

Core Insights - The European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older with two or more exacerbations in the prior 12 months, marking it as the first approved treatment for NCFB in the EU [1][4] - BRINSUPRI was reviewed under the EMA's Accelerated Assessment Pathway due to its significant public health interest [1] Company Overview - Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for serious diseases, with a commitment to underserved patient communities [14][15] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [14] Product Details - BRINSUPRI is a small molecule, once-daily oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1), indicated for the treatment of NCFB in patients aged 12 years and older [6] - The approval is based on data from the Phase 3 ASPEN and Phase 2 WILLOW studies, which demonstrated a 19.4% reduction in the annual rate of exacerbations for patients taking BRINSUPRI compared to placebo [3][8] Clinical Study Insights - The ASPEN study involved over 1,680 adult patients and 41 adolescent patients, showing significant improvements in exacerbation rates and lung function [8] - The WILLOW study included 256 adult patients and focused on the time to first pulmonary exacerbation, further supporting the efficacy of BRINSUPRI [9] Market Potential - An estimated 600,000 people in the EU are diagnosed with NCFB, with an additional two million potentially undiagnosed, indicating a substantial market opportunity for BRINSUPRI [2][10] - Insmed plans to engage with EU authorities to secure access to BRINSUPRI for eligible patients starting in early 2026 [4]

Core Insights - Insmed Incorporated will present six abstracts from the Phase 3 ASPEN study of BRINSUPRI (brensocatib) at the CHEST 2025 conference, highlighting its efficacy and potential impact on patients with non-cystic fibrosis bronchiectasis [1][3] Company Overview - Insmed is a global biopharmaceutical company focused on delivering innovative therapies for serious diseases, with a commitment to patient-first approaches [1][18] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [18] Product Information - BRINSUPRI (brensocatib) is a small molecule, once-daily oral treatment indicated for non-cystic fibrosis bronchiectasis in patients aged 12 and older [6][17] - The drug works by inhibiting neutrophil serine proteases, which are key drivers of chronic airway inflammation in bronchiectasis [6] Clinical Study Details - The ASPEN study was a global, randomized, double-blind, placebo-controlled Phase 3 trial involving over 1,700 patients across 391 sites in 35 countries [7] - The study evaluated the efficacy, safety, and tolerability of brensocatib, with a focus on symptom burden and structural lung changes [2][7] Upcoming Presentations - Presentations at CHEST 2025 will include analyses on the effects of brensocatib on symptom burden, CT outcomes, and its efficacy in patients with comorbid conditions like COPD [2][5] - Specific presentations will cover various subgroups, including Asian populations and patients experiencing pulmonary exacerbations [5][2]

Core Insights - Insmed Incorporated will present seven abstracts from its late-stage portfolio at the European Respiratory Society (ERS) 2025 Congress, highlighting its commitment to addressing serious respiratory diseases [1][2][3] Group 1: Treprostinil Palmitil Inhalation Powder (TPIP) - Data from the Phase 2 trial of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) will be featured in the ALERT session, showcasing significant clinical data [2][3] - The Phase 2b study of TPIP was a randomized, double-blind, multicenter, placebo-controlled trial involving 102 adult participants, aimed at evaluating the efficacy, safety, and pharmacokinetics of TPIP [7] - TPIP is a dry powder formulation administered via a capsule-based inhalation device, currently under investigation for treating PAH and other serious pulmonary disorders [6] Group 2: Brensocatib - Brensocatib, a small molecule oral inhibitor, is being evaluated for its efficacy and safety in treating non-cystic fibrosis bronchiectasis (NCFB) in both adult and pediatric patients [9][10] - The Phase 3 ASPEN trial involved over 460 trial sites across nearly 40 countries, assessing the treatment's impact on patients aged 12 years and older [10] - Presentations at the ERS Congress will include analyses of brensocatib's efficacy in Japanese patients and its health outcomes based on data from The Health Improvement Network (THIN) database [2][3] Group 3: Company Overview - Insmed is a global biopharmaceutical company focused on delivering innovative therapies for serious diseases, with a diverse portfolio of investigational medicines [21][22] - The company is recognized for its commitment to patient care and has been acknowledged as a top employer in the biopharmaceutical industry [22]